

QEEG abnormalities in cognitively unimpaired patients with delirium

INTRODUCTION

Delirium is an acute fluctuation in attention with reduced awareness, orientation, cognitive disturbances, sleep-wake cycle and emotional regulation. Psychomotor dysfunction represents a prominent feature defining three different delirium subtypes: hyperactive, marked by agitation, hypoactive, with lethargy and decreased motor activity, and mixed.¹

Delirium prevalence increases with age. It is particularly frequent during hospitalisation (20%–60% in elderly individuals), and is associated with high mortality rates.¹

Several factors may concur to delirium, as neurodegenerative diseases (it is considered a prodromal feature of dementia with Lewy bodies, DLB), electrolyte imbalance, alcohol or drug intoxication or withdrawal.¹ In neurodegenerative conditions central cholinergic deficiency is a leading hypothesised mechanism.² Delirium may result from an altered mechanism of external information processing due to derangement of intrinsic oscillation of cholinergic thalamocortical neurons, which modulates excitability of widespread cortical areas (the so-called thalamocortical dysrhythmia, TCD).^{2,3}

In the original TCD model, the abnormal inputs to oscillating thalamocortical neurons in quiet wakefulness disrupt their rhythmic neurotransmission to cortical neurons inducing the appearance of a dominant prealpha frequency (5.5–7.5 Hz) rhythms in the resting state eyes-closed electroencephalogram (rsEEG)

Table 1 Demographic, clinical and EEG characteristics of the two groups of patients included in the multicentre study

	Delirium group (n=65)	No-delirium group (n=41)	P value
Demographic characteristics			
Age	76.9 (11.9)	74.6 (12.1)	0.34
Females, n (%)	32 (49.2)	16 (39.0)	0.30
Death, n (%)	2 (3.1)	0 (0.0)	0.26
Delirium			
Onset from the admittance*	2.6 (3.1)	–	
Hyperkinetic, n (%)	17 (26.2)	–	
Hypokinetic, n (%)	32 (49.2)	–	
Mixed, n (%)	16 (24.6)	–	
LOS	16.9 (11.7)	4.0 (3.7)	<0.0001
Predisposing factors for delirium			
CCI†	5.8 (2.6)	3.9 (3.1)	0.02
Pneumonia, n (%)	11 (16.9)	2 (5.0)	0.03
Urinary tract infection, n (%)	6 (9.2)	2 (5.0)	0.23
Bedding, n (%)	19 (29.2)	9 (22.0)	0.41
Bladder catheter, n (%)	23 (35.4)	10 (24.4)	0.23
Disease at the admittance, n (%)			
Ischaemic stroke	19 (29.2)	8 (19.5)	0.26
Brain haemorrhage	5 (7.7)	6 (14.6)	0.26
Brain tumour	4 (6.2)	2 (4.9)	0.35
Other neurological diseases	12 (18.5)	14 (34.1)	0.06
Non-neurological diseases	25 (38.5)	11 (26.8)	0.22
EEG characteristics, n (%)			
Anterior derivations			
CSA 1	0 (0.0)	23 (62.2)	
CSA 1 plus	1 (1.9)	7 (18.9)	
CSA 2	10 (19.2)	4 (10.8)	
CSA 3	21 (40.4)	3 (8.1)	
CSA 4	20 (38.5)	0 (0.0)	
Pattern CSA			<0.001
Normal	0 (0.0)	23 (56.1)	
Pathological	52 (80.0)	14 (34.1)	
Artefact	13 (20.0)	4 (9.7)	
DFV			0.007
0	19 (29.2)	26 (63.4)	
0.5–1.5	14 (21.5)	4 (9.8)	
>1.5	19 (29.2)	7 (17.1)	
MDF‡	7.0 (2.5)	8.0 (2.0)	<0.001
Temporal derivations			
CSA 1	0 (0.0)	28 (70)	
CSA 1 plus	2 (3.5)	6 (15)	
CSA 2	17 (29.8)	5 (12.5)	
CSA 3	26 (45.6)	1 (2.5)	
CSA 4	12 (21.1)	0 (0.0)	
Pattern CSA			<0.001
Normal	0 (0.0)	28 (70)	
Pathological	57 (87.7)	13 (31.7)	<0.001
Artefact	8 (12.3)	1 (2.5)	0.001
DFV			0.001
0	21 (32.3)	29 (70.7)	
0.5–1.5	15 (23.1)	5 (12.2)	
>1.5	21 (32.3)	6 (14.6)	
MDF‡	7.5±1.8	8.0±2.0	<0.001
Occipital derivations			
CSA 1	0 (0.0)	29 (72.5)	
CSA 1 plus	2 (3.7)	6 (15)	
CSA 2	19 (35.2)	4 (10)	
CSA 3	24 (44.4)	1 (2.5)	

Continued

Table 1 Continued

	Delirium group (n=65)	No-delirium group (n=41)	P value
CSA 4	9 (16.7)	0 (0.0)	
Pattern CSA			<0.001
Normal	0 (0.0)	29 (70.7)	
Pathological	54 (83.1)	11 (26.8)	
Artefact	11 (16.9)	1 (2.4)	
DFV			<0.001
0	22 (33.9)	30 (73.2)	
0.5–1.5	14 (21.5)	5 (12.2)	
>1.5	18 (27.7)	5 (12.2)	
MDF†	7.0±1.5	9.0±1.5	<0.001

All data are reported as mean (Standard Deviation, (SD)), when not differently stated. All p-value were age and sex adjusted. Pathological CSA refers to the following CSA patterns: 1 plus, 2, 3 and 4.

*Delirium onset is expressed in days.

†Due to the not normal distribution, CCI was reported as median (IQR) and differences between groups were assessed through quantile regression analysis.

‡All variables were reported as median±IQR and differences assessed with quantile regression, age and sex adjusted.

CCI, Charlson Comorbidity Index; CSA, compressed spectral analysis; DFV, dominant frequency variability; LOS, hospital length of stay; MDF, mean dominant frequency; n, number of patients.

activity.^{2,4} As a consequence, consciousness level changes from quiet vigilance to drowsiness, sleep and dreaming, as well as visual hallucination, cognitive fluctuation and psychotic or dissociative states.^{2,5} All these conditions are characterised by altered states of consciousness, as typically occurs during delirium.^{1,4} Notably, the presence of those prealpha rhythms can be revealed measuring compressed spectral array (CSA), based on dominant frequency (DF) and DF variability (DFV).⁴ This study focused on testing the possible association between specific EEG CSA patterns with prealpha DF and delirium in cognitively unimpaired hospitalised patients.

METHODS

This double-design study includes a cross-sectional multicentre cohort study and a longitudinal single centre prospective study that was nested in the multicentre.

In the multicentre cross-sectional study, rsEEG activity was compared between hospitalised patients who manifested delirium and patients without delirium (between-group design). In the single-centre longitudinal study, rsEEG recorded in patients with delirium at the time of the acute delirium symptoms was compared with recordings performed when the symptom disappeared (at hospital discharge) and at 1-month follow-up (within-group design).

Online supplemental material 1 details methods of patient recruitment, of clinical and instrumental evaluation methods, and of EEG recording and analysis.

RESULTS

Cross-sectional multicentre study

Sixty-five subjects who experienced an episode of delirium during the hospital stay (delirium group) were enrolled and were matched for age and sex with 41 control subjects, admitted during the same period who did not develop delirium (no-delirium group).

Table 1 reports demographic, clinical and rsEEG characteristics of the two groups.

Mean DF was lower in delirium than no-delirium group ($p < 0.001$) at all EEG electrodes. Delirium group showed a prealpha DF (<8 Hz) whereas no-delirium group had a DF in the alpha range (≥ 8 Hz). DFV was higher in delirium than no-delirium group at all EEG electrodes (p -value ranging from 0.007 in anterior derivations to 0.001 in temporal derivations, to <0.001 in posterior derivations).

Abnormal CSA patterns (i.e., CSA 1 plus, 2, 3 and 4) were found in all (100%) delirium patients in all the derivations, whereas only 14 (34%) no-delirium patients had an abnormal EEG. No differences in EEG characteristics were found between subtypes of delirium (hypokinetic vs hyperkinetic), thus suggesting a common pathophysiological mechanism of the two clinical manifestations of delirium.

Single-centre longitudinal study

The longitudinal study was performed at centre 1 and included 23 patients with delirium who were recorded with rsEEG at resolution of delirium and at 1 month after hospital discharge.

One hundred per cent of them showed a CSA pattern >1 during delirium (online supplemental table 1). After delirium

resolution: 18 patients had an EEG normalisation, 2 patients still had an abnormal EEG (CSA pattern 2). In three patients, EEG was not interpretable due to artefacts. Similar results were observed at 1-month follow-up: one patient, with CSA 2 at both time of delirium and after its resolution, met the diagnostic criteria for DLB. Another patient met the criteria for mild cognitive impairment at 1-month follow-up. The remaining 21 patients had a CSA pattern 1 and resulted all cognitively unimpaired.

DISCUSSION

In this study, we hypothesised that delirium appearing during hospitalisation may be characterised by a prealpha rhythm, strictly related to TCD, as revealed by CSA markers derived from EEG analysis. In the cross-sectional multicentre study, patients with delirium showed lower DF and higher DFV at the prealpha/theta frequencies as compared with patients without delirium, thus supporting the working hypothesis that delirium may be a clinical manifestation induced by TCD.³ In contrast, 70% of the no-delirium patients showed a normal EEG with prominent posterior alpha rhythms.

These results of the cross-sectional design were corroborated by those of the longitudinal design. In most of delirium patients, the abnormal EEG-CSA markers and rsEEG, performed after recovering from delirium, disappeared by the hospital dismissal or 1-month follow ups.

It can be speculated that abnormal EEG-CSA patterns (i.e., prealpha rhythms) and delirium may be strictly associated, and may reflect TCD. Further investigations, including functional and microstructural

neuroimaging, and pharmacological studies, are needed to confirm the above speculation.

Two considerations result from our data. First, the cross-sectional and longitudinal association between EEG prealpha rhythms and delirium encourages the use of those EEG characteristics as a surrogate neurophysiological marker of delirium, which could be used in future clinical trials aimed to prevent and treat it in hospitalised patients.

Second, the pathophysiological mechanisms underlying the above of EEG specific alterations and delirium could explain cognitive fluctuations, which are a core feature of DLB. Interestingly, DLB patients show prealpha EEG rhythms⁴ similarly to patients with delirium. Therefore, the present results motivate future longitudinal studies following the patients who suffered from delirium overtime, to define the percentage of them showing prodromal DLB symptoms at follow-up.

Claudia Carrarini,¹ Dario Calisi,¹ Matteo Alessandro De Rosa,¹ Angelo Di Iorio,² Damiano D'Ardes,³ Raffaello Pellegrino,⁴ Stefano Gazzina,⁵ Andrea Pilotto,⁶ Andrea Arighi,⁷ Tiziana Carandini,⁷ Annachiara Cagnin,⁸ Stefano Mozzetta,⁸ Maurizio Gallucci,⁹ Domenico Marco Bonifati,¹⁰ Cinzia Costa,¹¹ Fabrizia D'Antonio,¹² Giuseppe Bruno,¹² Francesco Cipollone,³ Claudio Babiloni,^{13,14} Alessandro Padovani,⁶ Marco Onofri,⁶ Laura Bonanni³

¹Department of Neuroscience, Imaging and Clinical Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy

²Department of Innovative Technologies in Medicine & Dentistry, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy

³Department of Medicine and Aging Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy

⁴Department of Scientific Research, Campus Ludes, off-Campus Semmelweis, University of Lugano, Lugano, Switzerland

⁵Neurophysiology Unit, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

⁶Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁸Department of Neuroscience, Università degli Studi di Padova, Padova, Italy

⁹Cognitive Impairment Center, Marca Trevigiana Local Unit of Health and Social Services 2, Treviso, Italy

¹⁰Unit of Neurology, Department of Neuro-cardio-vascular, Ospedale Santa Maria di Ca Foncello, Treviso, Italy

¹¹Section of Neurology, S. Maria della Misericordia Hospital, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

¹²Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Roma, Italy

¹³Department of Physiology and Pharmacology, University of Rome La Sapienza, Rome, Italy

¹⁴San Raffaele Cassino Hospital, Cassino, Italy

Correspondence to Professor Laura Bonanni, Department of Medicine and Aging Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, 66100, Italy; l.bonanni@unich.it

Contributors CC: drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data. DC: major role in the acquisition of data. MADR: major role in the acquisition of data. ADI: analysis or interpretation of data. DD'A: major role in the acquisition of data. RP: major role in the acquisition of data. SG: major role in the acquisition of data. AP: major role in the acquisition of data. AA: major role in the acquisition of data. TC: major role in the acquisition of data. AC: drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data. SM: major role in the acquisition of data. MG: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data. DMB: major role in the acquisition of data. CC: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data. FD'A: major role in the acquisition of data. GB: major role in the acquisition of data. FC: Drafting/revision of the manuscript for content, including medical writing for content. CB: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data. AP: drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data. MO: drafting/revision of the manuscript for content, including medical writing for content. LB: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by Comitato Etico delle Province di Chieti e Pescara e dell'Università degli Studi 'G. d'Annunzio' di Chieti-Pescara Protocol code 2098. 11/6/2020. Protocol 'Neurodem' 26/7/2018, emend 2/8/2018. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and

responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2022-330010>).



To cite Carrarini C, Calisi D, De Rosa MA, et al. *J Neurol Neurosurg Psychiatry* 2023;**94**:251–254.

Received 19 July 2022

Accepted 5 October 2022

Published Online First 19 October 2022

J Neurol Neurosurg Psychiatry 2023;**94**:251–254. doi:10.1136/jnnp-2022-330010

ORCID iDs

Angelo Di Iorio <http://orcid.org/0000-0003-2899-146X>

Andrea Pilotto <http://orcid.org/0000-0003-2029-6606>

Annachiara Cagnin <http://orcid.org/0000-0002-0635-4884>

Marco Onofri <http://orcid.org/0000-0002-0480-2495>

Laura Bonanni <http://orcid.org/0000-0001-7443-9233>

REFERENCES

- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-5TM*. 5th ed. Arlington, VA, 2013.
- Llinás RR, Ribary U, Jeanmonod D, et al. Thalamic dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. *Proc Natl Acad Sci U S A* 1999;**96**:15222–7.
- Zobeiri M, van Luijtelaar G, Budde T, et al. The brain network in a model of thalamic dysrhythmia. *Brain Connect* 2019;**9**:273–84.
- Bonanni L, Perfetti B, Bifulchetti S, et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. *Neurobiol Aging* 2015;**36**:434–45.
- Mahowald MW, Schenck CH. NREM sleep parasomnias. *Neurol Clin* 1996;**14**:675–96.

SUPPLEMENTARY MATERIAL

METHODS

Inclusion criterium was the presence of delirium assessed by 4AT test and DSM-5 diagnostic criteria [1,2]. Exclusion criteria were mild cognitive impairment (MCI) or dementia, Parkinson's disease, traumas, seizures, previous psychiatric disease, alcohol abuse, pre-existing EEG abnormalities, thalamic lesions (including thalamic stroke), and vast cerebrovascular lesions or brain atrophy on neuroimaging exams.

The study was performed according to the declaration of Helsinki and its later amendments, and it was approved by the local ethical committee. A written consent for research purposes was obtained from all participants.

Participants

Multicenter study

A total of 140 consecutive patients, admitted from January 2021 to December 2021, were evaluated for the incidence of delirium during hospital stay and for the presence of exclusion criteria as reported. Participants referred to the following Centers: 1. Neurology Clinic and Internal Medicine Clinic of University G. d'Annunzio of Chieti-Pescara, "SS Annunziata" Hospital of Chieti; 2. Neurology Clinic of the University of Brescia; 3. Neurology Clinic of Policlinico of Milan; 4. Neurology Clinic of Padova University; 5. Neurology Clinic of Treviso Hospital; 6. Neurology Clinic of University of Perugia; 7. Neurology Clinic of Sapienza University of Rome.

65 patients with delirium were selected and were matched for age and sex with 41 control subjects, admitted during the same period, who did not develop delirium (no-delirium group).

All patients underwent a resting state EEG (rsEEG) recording before any pharmacological treatment was initiated.

At the admission, as for study design, medical history was collected from all patients and a complete neurological examination was also performed.

Delirium subtype (hypokinetic, hyperkinetic, and mixed) and the hospital length of stay (LOS) were reported. All predisposing factors for delirium occurrence were considered, such as comorbidities, concurrent lung and urinary infections, bedding, and the presence of bladder catheter. The presence of comorbidities was assessed using the Charlson Comorbidity Index (CCI) [3], which assigns a score ranging from 1 to 6 to each disease for a total of different sixteen pathologies. The final score, which ranges up to 37, is calculated also combining the patient age.

Possible electrolyte, metabolic, hematologic, respiratory alterations were promptly corrected at admission.

Supplementary Figure 1 shows the flow chart of patient recruitment.

Single-center longitudinal study

The patients admitted to Center 1 wards, who developed delirium during hospital stay and included in the multicenter cohort study, were recorded with rsEEG at resolution of delirium and at 1 month after hospital discharge.

At the time of the second recording, 10 patients (those with hyperkinetic or mixed delirium) had been treated with iv Benzodiazepine (Lorazepam or Diazepam) (3 patients), im Haloperidol (5 patients) or Haloperidol + Benzodiazepines (2 patients). These treatments were promptly withdrawn after resolution of delirium. The third recording was therefore performed off treatments.

4AT

The 4AT [1] is a brief screening test characterized by high sensitivity and specificity in detecting the presence of delirium.

The scale is formed by four different items, which evaluate the state of alertness (first item), cognition (second and third items), and either the acute or fluctuating onset (fourth item).

The final score can range from 0 to 12 points. Delirium is diagnosed when the score is equal or superior to 4, whereas when it is between 1 and 3 a cognitive decline should be considered and better evaluated.

Quantitative EEG recordings

Quantitative EEG (QEEG) was recorded with Ag/AgCl disk scalp electrodes from 19 scalp derivations (Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T4, T5, T6, O1, and O2) placed according to the international 10–20 system, with two additional electrodes placed on A1 and A2. Recordings were acquired continuously with subjects resting comfortably, with their eyes closed. Eye movements were simultaneously monitored from two additional channels. Two pairs of bipolar recording channels for respiration and electrocardiogram were also applied. Muscular or tremor artefacts were controlled using supplementary derivations.

EEG data analysis

EEG recordings were obtained at each Center and centrally analyzed at Center 1.

QEEG was acquired as a continuous signal for 30 minutes and visually inspected for current clinical interpretation or artefact detections. QEEG signal was stored to be epoched in off-analysis setting as series of 2-second-long epochs. Electrodes from anterior (Fp1, Fp2, Fz, F3, F4, F7, F8), posterior (P3, P4, Pz, O1, O2), and temporal (T3, T4, T5, T6) derivations were considered for the analysis.

Ninety blocks of artifact-free 2-second-long epochs appearing consecutively were selected off-line by visual inspection. Fast Fourier Transform (FFT) was applied on each epoch allowing a frequency resolution of 0.5 Hz. The obtained spectra values were then processed to compute a mean power spectrum for each channel and divided automatically into four different frequency bands, as follows: delta (3–4 Hz), theta (4.5–5.5 Hz), fast theta or pre-alpha (6–7.5 Hz), and alpha (8–12 Hz).

EEG traces were quantified by the following mathematical descriptors: dominant frequency (DF), which is the frequency where the spectral power value was greatest for each epoch, and dominant frequency variability (DFV), expressing the variability of DF across the 90 analyzed epochs.

The final pattern of Compressed Spectral Array (CSA), which represents the epoch-to-epoch representation of EEG-FFT for each derivation, was then calculated. Indeed, based on mean DF (MDF), mean DFV, and frequency prevalence (FP), which expresses the percentage of epochs where dominant alpha, pre-alpha, or theta-delta frequencies were found, six different QEEG activity patterns were classified, as follows: pattern 1 (stable alpha), corresponding to the presence of a dominant alpha in 60% or more of analyzed epochs ($DF \geq 8$ Hz, $DFV < 1.6$ Hz); pattern 1 plus, characterized by DF in the alpha frequency band with intrinsic variability ($DFV > 1.5$ Hz); pattern 2 (unstable alpha with pre-alpha or theta/delta), described by the presence of dominant alpha ($DF \geq 8$ Hz, $DFV > 2$ Hz) in $< 50\%$ of epochs with dominant pre-alpha or theta ($DF < 8$ Hz) in 40% or more of epochs; pattern 3 (stable pre-alpha), consisting of the complete absence of alpha and the presence of a stable pre-alpha ($DF < 8$ Hz, $DFV < 1.0$ Hz) in 70% or more of analyzed epochs; pattern 4 (unstable pre-alpha with theta/delta), consisting of absence of alpha, dominant pre-alpha in $< 70\%$ of analyzed epochs, with dominant theta or delta in 40% or more of epochs ($DFV < 2.0$ Hz); pattern 5 (unstable low frequency), characterized by the absence of both alpha and pre-alpha dominant activity in more than two subsequent epochs ($DFV < 4$ Hz) [4,5].

Statistical analysis

Gaussian continuous variables were reported as mean \pm standard deviation (SD), and for not gaussian as median \pm IRQ (interquartile range). Dichotomous and categorical variables were reported as absolute numbers and percentages. Differences between the two groups (delirium group and no-delirium group) were evaluated by analysis of variance, by quantile regression to model the effects of covariates on quantiles of a response variable, and chi-square test for continuous and categorical variables.

A post hoc power of study, effect and estimate sample size calculation were performed. In the cross-sectional study, considering the two samples (65 patients with delirium vs. 41 patients without delirium) and considering that the percentage of EEG alterations (CSA pattern 2 to 4) was 98% in the case sample and 10.9% in the control sample, the power of study is above 90%.

By using the Binomial Effect Size Display (BESD) which in our study results to be 63%, the estimate size calculation is 15 patients per group.

For the longitudinal study, we considered that 30% of patients without delirium included in the cross-sectional study showed EEG abnormalities. Therefore, we would expect that 30% of the patients, included in the longitudinal study, should still have EEG abnormalities after resolution of delirium. In our cohort only 2 (10%) patients out of the 23 included in the longitudinal study still had EEG abnormalities at follow-up. Based on these results, the power analysis showed a power of 72% and an estimated sample size of 29 patients. Further confirmation studies are needed.

All analyses were age and sex adjusted since these effects could interfere with dependent and independent variables.

All statistical analyses were performed using SAS software rel.9.4.

SUPPLEMENTARY TABLE AND FIGURES

Supplementary Table 1: Demographic, clinical and electrophysiological characteristics of delirium group considering the single Center study (Center 1).

Demographic characteristics		p-value				
Age	83.1 (6.5)	0.02				
Females, <i>n</i> (%)	12 (52.2)	0.8				
Death, <i>n</i> (%)	2 (8.7)	0.3				
Delirium						
Onset from the admittance *	2.3 (2.2)	0.6				
Hyperkinetic, <i>n</i> (%)	5 (21.7)	0.6				
Hypokinetic, <i>n</i> (%)	6 (26.1)	0.06				
Mixed, <i>n</i> (%)	12 (52.2)	0.01				
LOS						
	14.9 (14.0)	0.5				
Predisposing factors for delirium						
CCI	6.6 (1.6)	0.2				
Pneumonia, <i>n</i> (%)	3 (13.0)	0.6				
Urinary tract infection, <i>n</i> (%)	0 (0)	0.1				
Bedding, <i>n</i> (%)	15 (65.2)	0.002				
Bladder catheter, <i>n</i> (%)	15 (65.2)	0.01				
Disease at the admittance, <i>n</i> (%)						
Ischemic stroke	13 (56.5)	0.02				
Brain hemorrhage	5 (21.7)	0.5				
Brain tumor	1 (4.3)	0.7				
Other neurological diseases	0 (0)	0.03				
Non neurological diseases	2 (8.6)	0.008				
EEG characteristics						
	Anterior		Temporal		Posterior	
	DF	DFV	DF	DFV	DF	DFV
During delirium	6.6 (1.0)	1.8 (1.3)	7.0 (1.0)	1.4 (1.4)	7.2 (0.4)	1.2 (1.4)
After resolution	8.4 (1.0)	0.6 (0.5)	8.5 (0.9)	0.5 (0.7)	8.5 (0.5)	0.5 (0.5)
1-month follow-up	8.2 (0.9)	0.6 (0.9)	8.5 (0.8)	0.5 (0.6)	8.5 (0.5)	0.4 (0.5)


All data are reported as mean (standard deviation, SD), when not differently stated.

* Delirium onset is expressed in days.


P-values refer to comparison with delirium multicenter cohort.

Abbreviations: *n*= number of patients; CCI= Charlson Comorbidity Index; LOS= hospital length of stay; DF= Dominant frequency; DFV= Dominant frequency variability.


Supplementary Figure 1: The flow chart of patient recruitment.



Supplementary Figure 2: Different CSA patterns from occipital derivations in five illustrative patients included in no-delirium group and delirium group.



Supplementary Figure 3: Example of a patient's pathological EEG pattern and its recovery to normal pattern after the episode of delirium and at 1-month follow-up from three different derivations (anterior, temporal, and posterior).



LIMITATIONS OF THE STUDY

Risk factors for development of delirium

The risk of delirium increases with increasing frequency and severity of comorbidities.

Comorbidities in our study was assessed by the CCI, which provides a simple and valid tool for estimating the risk of death associated with comorbidity and has proven to be reliable in different types of outcomes research [6–8].

Delirium risk factors may differ between medical and surgical patients where the latter are exposed to iatrogenic factors such as anesthetic agents or surgical procedures. In our cohort none of the patients were surgical or exposed to anesthetic agents or had fractures or other causes of neuropathic pain, which could engender TCD.

Parkinson's disease patients were also excluded, since inhibitory projections from the basal ganglia in the pallido-thalamic tract might provoke TCD.

Patients with trauma were excluded because traumas can disrupt or modulate cortical function over spatially distributed areas through diaschisis, altering the physiological state of distant regions including the thalamocortical system [9].

Finally, all the possible metabolic, hematologic, electrolyte, respiratory imbalances were corrected in all the patients.

Most patients enrolled showed cerebrovascular disorders. This is a sensitive confounding factor as cortical lesions resulting from stroke can lead to excessive hyperpolarization of thalamic neurons, switching them to a low threshold bursting regime by de-inactivating calcium currents [10,11]. This switch may induce TCD dynamics and may entrain thalamo-cortical pathways, propagating low-frequency oscillations into the neocortex. To mitigate this confounding factor, we excluded from the study patients with thalamic and extensive hemispheric lesions [12].

As mentioned in the previous paragraph, the genesis of delirium is multifactorial [13] and generally all conditions that can induce a neuroinflammatory process are potential causes of delirium.

~ ~

Through the action of inflammatory agents, a cascade of events is activated, which culminates in endothelial and microvascular damage and blood–brain barrier alterations.

Among all the delirium predisposing factors considered in the study, delirium group showed a higher CCI score ($p=0.02$), a higher LOS ($p<0.0001$), and a higher occurrence of concurrent pneumonia ($p=0.02$). Therefore, we cannot rule out the role of comorbidities and possible inflammatory state related to them as factors influencing the thalamocortical system function, since a link between TCD and severe sepsis has been reported [14]. Neuropathological processes following sepsis additionally lead to the development of TCD, as the patients' EEG display the distinctive slowing of the DF into pre-alpha range [14]. We could overcome this concern by demonstrating that EEG after delirium recovery normalized, even though the underlying cause of hospital stay was still active.

Methodological remarks

The TCD involvement in the pathogenesis of delirium was not corroborated by functional MRI study or a MRI study of the microstructural alterations of thalamocortical system. These studies could be helpful to clarify the involvement of the thalamus in the genesis of EEG alterations in delirium. However, this is an ecological study, performed in hospitalized patients, who, per their condition, could not undergo MRI during delirium.

A further methodological limitation lies in the small sample size of the longitudinal study, which makes the results not generalizable. The number of followed-up patients need to be increased in a further longitudinal study.

Finally, even though we did not find differences in EEG abnormalities between hypokinetic vs. hyperkinetic delirium, this might be explained by the sample size of the cross-sectional study. Increasing the number of studied patients could help proving the datum.

..

SUPPLEMENTARY REFERENCES

- 1 Bellelli G, Morandi A, Davis DHJ, *et al.* Validation of the 4AT, a new instrument for rapid delirium screening: A study in 234 hospitalised older people. *Age Ageing* 2014;**43**:496–502. doi:10.1093/ageing/afu021
- 2 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5TM. Arlington. Arlington, VA 2013.
- 3 Charlson M, Szatrowski TP, Peterson J, *et al.* Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;**47**:1245–51. doi:10.1016/0895-4356(94)90129-5
- 4 Bonanni L, Thomas A, Tiraboschi P, *et al.* EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. *Brain* 2008;**131**:690–705. doi:10.1093/brain/awm322
- 5 Bonanni L, Perfetti B, Bifulchetti S, *et al.* Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. *Neurobiol Aging* 2015;**36**:434–45. doi:https://doi.org/10.1016/j.neurobiolaging.2014.07.009
- 6 Ofori-Asenso R, Zomer E, Chin KL, *et al.* Effect of comorbidity assessed by the Charlson comorbidity index on the length of stay, costs and mortality among older adults hospitalised for acute stroke. *Int J Environ Res Public Health* 2018;**15**:1–11. doi:10.3390/ijerph15112532
- 7 Tuty Kuswardhani RA, Henrina J, Pranata R, *et al.* Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. *Diabetes Metab Syndr Clin Res Rev* 2020;**14**:2103–9. doi:10.1016/j.dsx.2020.10.022
- 8 Sundararajan V, Henderson T, Perry C, *et al.* New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol* 2004;**57**:1288–94. doi:10.1016/j.jclinepi.2004.03.012
- 9 Dubovik S, Pignat J-M, Ptak R, *et al.* The behavioral significance of coherent resting-state oscillations after stroke. *Neuroimage* 2012;**61**:249–57.

- doi:10.1016/j.neuroimage.2012.03.024
- 10 Neske GT. The slow oscillation in cortical and thalamic networks: Mechanisms and functions. *Front Neural Circuits* 2016;**9**:1–25. doi:10.3389/fncir.2015.00088
 - 11 Ehling P, Göb E, Bittner S, *et al.* Ischemia-induced cell depolarization: Does the hyperpolarization-activated cation channel HCN2 affect the outcome after stroke in mice? *Exp Transl Stroke Med* 2013;**5**:1–8. doi:10.1186/2040-7378-5-16
 - 12 van Wijngaarden JBG, Zucca R, Finnigan S, *et al.* The Impact of Cortical Lesions on Thalamo-Cortical Network Dynamics after Acute Ischaemic Stroke: A Combined Experimental and Theoretical Study. *PLoS Comput Biol* 2016;**12**:e1005048. doi:10.1371/journal.pcbi.1005048
 - 13 Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. *Lancet (London, England)* 2014;**383**:911–22. doi:10.1016/S0140-6736(13)60688-1
 - 14 Götz T, Baumbach P, Huonker R, *et al.* Slowed peak resting frequency and MEG overactivation in survivors of severe sepsis and septic shock. *Clin Neurophysiol* 2016;**127**:1247–53. doi:https://doi.org/10.1016/j.clinph.2015.07.021